Downloads: 6 | Views: 132 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1
Review Papers | Physiology | Saudi Arabia | Volume 13 Issue 2, February 2024 | Rating: 5.4 / 10
Serum Cystatin C Level as an Early Biomarker for Detecting Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus: A Meta - Analysis Study
Samia Saeed Alawad [2] | Ibrahim Abdulrahim Ali | Mohammed Abd Rhaman Adris Abdallah
Abstract: There are many research addressed the importance of biomarkers for early prediction of diseases thus increasing the chance for treatment. This meta-analysis study aims to evaluate serum Cystatin C as early biomarker for predicting diabetic nephropathy in patients with type 2 diabetes. Methods: Searching on five database studies which carried out from 2019-2023. Ten studies included were analyzed using ?meta?, ?metasens? and ?diagmeta? packages. R version 4.2.2. We calculated values for serum cystatin C in DM and DM with nephropathy, cut-off value, specificity, sensitivity, the area under the curve (AUC) and Receiver operating characteristic curve (ROC). The Results showed level of cystatin C was significantly higher in DM with nephropathy group [MD = 1.22, 95% CI (-2.22,-0.23), p-value = 0.02]. The pooled data was heterogeneous (I2 = 98%, p-value < 0.01and pooled sensitivity 0.73 and specificity 0.73. The pooled DOR of cystatin C was [69.9, 95% CI (4.68, 10.26). optimal cutoff point was [0.6932, 95% CI (0.2050; 0.9519). The pooled DOR of cystatin C was [69.9, 95% CI (4.68, 10.26). Conclusion: This study demonstrated that cystatin C is a potential early biomarker for predicting diabetic nephropathyin type 2 diabetic patients.
Keywords: Cystatin C, Diabetic nephropathy, meta-analysis, biomarkers
Edition: Volume 13 Issue 2, February 2024,
Pages: 483 - 487